reports
- Sean Conroy
Oxford Cannabinoid Technologies - Termination of coverage
Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
- Sean Conroy
Oxford Cannabinoid Technologies - Early signs of revival in clinical a...
Oxford Cannabinoid Technologies (OCT) has announced its H124 results (to end-October 2023), an eventful period for the company, marked by successful clinical progression of lead asset OCT461201, albeit with some funding challenges. Key highlights included the initiation and subsequent positive safety data from OCT’s first Phase I clinical trial (Programme 1) and a foray into oncology (Programme 4). Tight funding conditions halted subsequent clinical progress, although the recently announced £1.3...
- Sean Conroy
Oxford Cannabinoid Technologies - Poised to progress to Phase II pendi...
Oxford Cannabinoid Technologies (OCT) has announced the completion of its Phase I trial, a single ascending dose study for its lead drug candidate, OCT461201. The results of the Phase I study demonstrated safety and tolerability across the tested doses and OCT will prepare to proceed to Phase II provided it is able to raise funds in a timely manner. We continue to expect the subsequent Phase II trial to be conducted in patients with neuropathic pain associated with chemotherapy-induced periphera...
- Sean Conroy
Oxford Cannabinoid Technologies - Clinical headway rests on funding
Oxford Cannabinoid Technologies (OCT) has shared its FY23 results and summarised its ongoing activities. OCT completed preclinical research for OCT461201 (programme 1) and in July 2023 the first healthy volunteer was dosed in the Phase I safety study; results are expected in Q3 CY23. Management believes this programme will be Phase II ready by Q4 CY23, and plans to target neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) and visceral pain in irritable bowel syndr...
- Daniel Appiah
- John Savin PhD
- Robin Davison
OCT enters clinical development with 201
Oxford Cannabinoid Technologies (OCT) develops a range of cannabinoid-derived pharmaceuticals. The key news is that the Phase 1 dose and safety study of its lead indication OCT461201 (“201”) with up to 32 volunteers has started.The phase I should be followed by a phase II in patients with establish
- Sean Conroy
Oxford Cannabinoid Technologies - A move away from generic pain treatm...
Oxford Cannabinoid Technologies (OCT) is focused on developing cannabinoid medicines for the treatment of pain and other indications. Lead asset OCT461201 is a synthetic, endocannabinoid system-targeting new chemical entity (NCE) being developed for the treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) and visceral pain in irritable bowel syndrome (IBS). Preclinical studies have demonstrated positive early signals of efficacy in pain indications and ...
- Daniel Appiah
- John Savin PhD
- Robin Davison
Phase 1 approval for lead chronic pain drug
Oxford Cannabinoid Technologies (OCT) develops non-opioid, non-addictive pain pharmaceuticals. Its lead product OCT461201 (“201”) is an oral product to relieve peripheral nerve pain caused by cancer chemotherapy (CIPN) and irritable bowel syndrome (IBS). Management estimate that the global CIPN mar
- Daniel Appiah
- John Savin PhD
- Robin Davison
Interim results, moving into clinical
Oxford Cannabinoid Technologies (OCT) develops non-opioid, non-addictive pain pharmaceuticals. The lead product, OCT461201 (“201”), is an oral product to relieve peripheral nerve pain caused by cancer chemotherapy (CIPN). OCT estimates that the CIPN market is worth £1.7bln with 6.4% CAGR forecast.
EQS-News: Proactive research analyst John Savin on Oxford Cannabinoid ...
EQS-News: Oxford Cannabinoid Technologies Holdings PLC Proactive research analyst John Savin on Oxford Cannabinoid Technologies 15.12.2022 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive UK Ltd 3News Source: News Direct 15.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Release...
EQS-News: Oxford Cannabinoid Technologies 'very confident' heading int...
EQS-News: Oxford Cannabinoid Technologies Holdings PLC Oxford Cannabinoid Technologies 'very confident' heading into 2023 15.12.2022 / 10:36 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive UK Ltd 3News Source: News Direct 15.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Arch...
- Daniel Appiah
- John Savin PhD
- Robin Davison
Oxford Cannabinoid Technologies: Clinical objectives confirmed for 202...
Oxford Cannabinoid Technologies (OCT) develops non-opioid pain pharmaceuticals. The lead product, OCT461201 (“201”), is an oral product to relieve peripheral nerve pain caused by cancer chemotherapy (CIPN). In a trading update (12 December 2022), management indicates that 201 will enter the clinica
EQS-News: Oxford Cannabinoid Technologies appoints new CEO
EQS-News: Oxford Cannabinoid Technologies Holdings PLC Oxford Cannabinoid Technologies appoints new CEO 05.12.2022 / 15:38 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive UK Ltd 3News Source: News Direct 05.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -news.com ...
EQS-News: Oxford Cannabinoid Technologies nearly ready for new phase 1...
EQS-News: Oxford Cannabinoid Technologies Holdings PLC Oxford Cannabinoid Technologies nearly ready for new phase 1 trial 15.11.2022 / 16:22 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactiveProactive UK Ltd 3News Source: News Direct 15.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Rele...
- Daniel Appiah
- John Savin PhD
- Robin Davison
Clinical 2023 in prospect
Oxford Cannabinoid Technologies (OCT) develops non-opioid pain pharmaceuticals. After further, positive preclinical research, there are two lead products heading for clinical development. The first is OCT461201 (“201”), an oral product to relieve peripheral nerve pain caused by cancer chemotherapy
DGAP-News: Data from pre-clinical study of OCT461201 shows positive re...
DGAP-News: Oxford Cannabinoid Technologies Holdings Plc Data from pre-clinical study of OCT461201 shows positive results 08.03.2022 / 21:26 The issuer is solely responsible for the content of this announcement. Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to announce positive results from a pre-clinical pain study for its lead compound, OCT461201, targeting the global Chemotherapy Induced Peripheral Neuropathy ('CIPN') t...
- Daniel Appiah
- John Savin PhD
FY22 Interim results
Oxford Cannabinoid Technologies (OCT) is a UK-based pharmaceutical company developing next-generation, non-addictive pain medications to replace opioids. Management estimated that the market will grow to £42.5bln by 2027 and OCT aims to gain an aggressive share of this market. OCT's candidates targ
- Ed Stacey
Oxford Cannabinoid Technologies - initiation report
Oxford Cannabinoid Technologies (OCT) is a UK-based pharmaceutical company specialising in drug development from cannabinoids (compounds derived from cannabis). The company aims to become a leader in developing licensed prescription medicines that target the endocannabinoid system with a primary fo
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.